Overview

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Status:
WITHDRAWN

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1

Phase:

PHASE2

Details

Lead Sponsor:

Sutro Biopharma, Inc.